Synergy Pharmaceuticals announced that oral dosing of healthy volunteers has begun in a Phase I clinical trial of SP-333, a guanylate cyclase C, or GC-C, agonist for the treatment of inflammatory bowel disease, IBD, including ulcerative colitis, or UC. SP-333 has exhibited potent anti-inflammatory activity in animal studies of colitis, displaying a novel mechanism-of-action that the company believes could provide a new way to treat UC patients with mild-to-moderate disease.
- Pharmaceuticals & Drug Trials
- inflammatory bowel disease
- ulcerative colitis